TIRmed Pharma, a biotechnology company developing innovative treatments for
autoimmune skin diseases, has appointed Peder Walberg and Christian Krog-Jensen
to its Board of Directors. The appointments come at a pivotal stage as the company
intensifies preparations for the upcoming Phase Ib clinical trial of its lead drug
candidate, TIR-C, targeting atopic dermatitis (eczema).
TIRmed is advancing a next-generation treatment for atopic dermatitis, designed to offer
patients effective relief with fewer side effects and simpler administration. The treatment
targets the root causes of the disease rather than merely alleviating symptoms. In preclinical
studies, five topical applications over two weeks have resulted in up to 15 months of
sustained relief.
The new board members strengthen the company’s strategic capabilities in drug
development, business strategy, and investment—areas that are critical on the path toward
the clinical phase.
“We are very pleased to welcome Peder Walberg and Christian Krog-Jensen to the board.
Their complementary expertise in clinical development, strategic planning, and financing will
be essential as we bring TIR-C into the clinic and position the company for long-term
success,” says Leo Holmgren, CEO of TIRmed Pharma.
Peder Walberg was appointed following discussions with Sciety, one of TIRmed’s investors,
who introduced him as a strong candidate with particular expertise in clinical and commercial
development.
Peder Walberg is a licensed physician and economist, currently active as an investor and
advisor in the life science sector, and a board member of Immedica Pharma AB. Walberg
has a long-standing career in life science, with extensive experience in drug development
and commercialization—including leading the Swedish launch of Elidel for atopic dermatitis
during his time at Novartis. He has played a central role in strategic decision-making,
regulatory planning, and negotiations with licensing partners and acquirers. His previous
roles include key positions at Sobi, Wilson Therapeutics, Immedica Pharma AB, and Egetis
Therapeutics.
“TIRmed has a strong team and a drug candidate with the potential to transform the
treatment landscape for atopic dermatitis. I look forward to contributing my experience as the
company moves toward clinical development and commercialization,” says Peder Walberg.
Christian Krog-Jensen is Investment Manager at Almi Invest, where he focuses on
identifying and supporting promising companies in the life science sector. With a background
in medicinal chemistry, he combines a strong scientific foundation with extensive experience
in business development and research commercialization. He previously led the DRIVE
incubator at KI Innovations, where he coached several successful startups. He is also an
inventor with multiple patents and co-founder and leader in several biotech companies,
moving drug candidates into clinical trials.
“There is a clear scientific rationale behind TIRmed’s approach, and I see strong potential in
the company’s strategy. I’m excited to support the team in the next phase,” says Christian
Krog-Jensen.
About TIRmed Pharma
TIRmed Pharma is a biotechnology company developing next-generation
immunomodulatory therapies for autoimmune skin diseases, with an initial focus on Atopic
Dermatitis (eczema). The company’s drug candidate, TIR-C, is a topical oligonucleotide-
based treatment that regulates immune responses and targets the disease’s underlying
mechanisms rather than just controlling symptoms. Promising preclinical results support its
potential to provide long-lasting relief and reduce treatment burden. Building on expertise in
immunology and drug development, the company is pioneering new solutions in
dermatological immunotherapy to enable more targeted and effective treatment options.